A STAT6 p.D419G variant causing severe multi-organ allergic disease: case report on a transformative response with dupilumab

Abstract Background Signal transducer and activator of transcription 6 (STAT6) gain-of-function (GOF) variants cause severe, early-onset multi-organ allergic disease through IL-4/IL-13-mediated type 2 immunity. We report a patient with a STAT6 p.D419G variant and her remarkable response to targeted therapy. Case presentation A 39-year-old woman of Middle Eastern origin presented with lifelong severe atopic disease beginning before age 2, including treatment-refractory atopic dermatitis, severe asthma requiring intubation, IgE-mediated food allergies, eosinophilic gastrointestinal disease, and recurrent infections. She demonstrated persistently elevated serum IgE (peak 16,000–17,000 KU/L and >5000 KU/L throughout her mid-thirties) and eosinophilia (peak 2.35 × 10⁹/L). Whole exome sequencing identified a heterozygous STAT6 variant (NM_001178079.2) c.1256A>G (p.D419G). Notably, brain MRI revealed vascular malformations in the circle of Willis, including hypoplastic vertebrobasilar arteries and persistent trigeminal artery. She required daily prednisone (average 20 mg) for years, resulting in cataracts and low bone mineral density. At age 34, dupilumab (300 mg subcutaneously every 2 weeks) was initiated, targeting the dysregulated IL-4/IL-13 pathway. Over five years of treatment, she achieved complete corticosteroid cessation, with her Eczema Area and Severity Index declining from 65 (very severe) to 2.2 (mild), normalization of spirometry, and improvement in biomarkers (IgE decreased to 2792 KU/L, eosinophils to 0.2 × 10⁹/L). Her quality of life improved dramatically, enabling the pursuit of personal, academic, and professional goals. Conclusion This case demonstrates the severe phenotype of STAT6-GOF and highlights the transformative potential of precision medicine using IL-4Rα-blocking therapy in select patients, although standardized treatment guidelines for this rare disease are lacking. Early recognition of STAT6-GOF clinical "red flags" and genetic testing enables targeted treatment, avoiding prolonged corticosteroid exposure and its complications. The presence of cerebrovascular malformations warrants further investigation into potential associations with STAT6-GOF.

Authors

Institutions

Publication Details

Journal
Allergy Asthma and Clinical Immunology
Published
2026-11-15
DOI
https://doi.org/10.1186/s13223-026-01083-5
Primary Topic
Immunodeficiency and Autoimmune Disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A STAT6 p.D419G variant causing severe multi-organ allergic disease: case report on a transformative response with dupilumab

Hanan Ahmed, Laila Sheather
2 links
Allergy Asthma and Clinical Immunology
Immunodeficiency and Autoimmune Disorders
article

A STAT6 p.D419G variant causing severe multi-organ allergic disease: case report on a transformative response with dupilumab

Hanan Ahmed, Laila Sheather
article en

Abstract

Abstract Background Signal transducer and activator of transcription 6 (STAT6) gain-of-function (GOF) variants cause severe, early-onset multi-organ allergic disease through IL-4/IL-13-mediated type 2 immunity. We report a patient with a STAT6 p.D419G variant and her remarkable response to targeted therapy. Case presentation A 39-year-old woman of Middle Eastern origin presented with lifelong severe atopic disease beginning before age 2, including treatment-refractory atopic dermatitis, severe asthma requiring intubation, IgE-mediated food allergies, eosinophilic gastrointestinal disease, and recurrent infections. She demonstrated persistently elevated serum IgE (peak 16,000–17,000 KU/L and >5000 KU/L throughout her mid-thirties) and eosinophilia (peak 2.35 × 10⁹/L). Whole exome sequencing identified a heterozygous STAT6 variant (NM_001178079.2) c.1256A>G (p.D419G). Notably, brain MRI revealed vascular malformations in the circle of Willis, including hypoplastic vertebrobasilar arteries and persistent trigeminal artery. She required daily prednisone (average 20 mg) for years, resulting in cataracts and low bone mineral density. At age 34, dupilumab (300 mg subcutaneously every 2 weeks) was initiated, targeting the dysregulated IL-4/IL-13 pathway. Over five years of treatment, she achieved complete corticosteroid cessation, with her Eczema Area and Severity Index declining from 65 (very severe) to 2.2 (mild), normalization of spirometry, and improvement in biomarkers (IgE decreased to 2792 KU/L, eosinophils to 0.2 × 10⁹/L). Her quality of life improved dramatically, enabling the pursuit of personal, academic, and professional goals. Conclusion This case demonstrates the severe phenotype of STAT6-GOF and highlights the transformative potential of precision medicine using IL-4Rα-blocking therapy in select patients, although standardized treatment guidelines for this rare disease are lacking. Early recognition of STAT6-GOF clinical "red flags" and genetic testing enables targeted treatment, avoiding prolonged corticosteroid exposure and its complications. The presence of cerebrovascular malformations warrants further investigation into potential associations with STAT6-GOF.

Allergy Asthma and Clinical Immunology
Toronto Metropolitan University (CA), McMaster University (CA)
McMaster University
Good health and well-being
Immunodeficiency and Autoimmune Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon